Lv620
2720 积分 2024-12-29 加入
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
3天前
求助中
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort
23天前
已关闭
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
3个月前
已完结
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
3个月前
已完结
Risankizumab for Ulcerative Colitis
5个月前
已完结
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
5个月前
已完结
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
5个月前
已完结
皖公网安备34019202002308
